|
Orthologous residues
|
|
NMDAR2A (human): S1232‑p, NMDAR2A (mouse): S1232‑p, NMDAR2A (rat): S1232‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
'neuron, hippocampal, CA1 pyramidal'-brain [CDK5 (rat)], 'neuron, hippocampal, CA1 pyramidal'-brain [NMDAR2A (rat)]
|
|
Cellular systems studied:
tissue
|
|
Species studied:
rat
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CDK5 (rat)
|
genetic transfer of dominant-negative enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ischemia
|
|
|
|
increase
|
|
|